AstraZeneca said its Covid-19 vaccine contributed $275 million (R3.95 billion) to first-quarter sales but shaved three cents per share from its earnings, as it posted better-than-expected results and forecast growth in the second half.
We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can
trust. For only R75 per month, you have access to
a world of in-depth analyses, investigative journalism,
top opinions and a range of features. Journalism
strengthens democracy. Invest in the future today.